News

Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection. For the global MOVe-AHEAD study, individuals

Teva Pharmaceuticals and MedinCell’s new drug application (NDA) for their drug, TV-46000/mdc-IRM to treat schizophrenia has been accepted by the US Food and Drug Administration (FDA). Intended for

Claimed to have high clinical potential to treat Covid-19, Silmitasertib acts on the protein kinase CK2 pathway. As a CK2-inhibitor, it is believed to hinder the active viral

The US Food and Drug Administration (FDA) has approved an expanded indication for UCB’s Briviact (brivaracetam) CV as monotherapy or adjunctive therapy for the treatment of partial-onset seizures

Roche has decided to voluntarily withdraw the US accelerated approval for Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) to treat patients with PD-L1-positive metastatic triple-negative breast cancer (mTNBC).

Inovio has secured approval from the Brazilian health regulatory agency, ANVISA, to start the international Phase III part of Phase II/III INNOVATE clinical trial assessing its Covid-19 deoxyribonucleic

Japan has approved AstraZeneca’s Forxiga (dapagliflozin) to treat chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Japanese Ministry of Health, Labour and Welfare

Eli Lilly and Company and Lycia Therapeutics have signed a multi-year collaboration and licensing agreement for the discovery and development of novel lysosomal targeting chimera (LYTAC) degraders. The

Pfizer and its partner BioNTech are seeking approval from the US Food and Drug Administration (FDA) for their booster dose of Covid-19 vaccine, Comirnaty, for individuals aged 16